The aflibercept biosimilar Pavblu has been marketed by Amgen since October 2024, after a District Court denied Regeneron’s motion for a preliminary injunction against the biosimilar maker. A Court of Appeals decided last week that Regeneron’s patent violation argument was not persuasive, validating Amgen’s decision to launch Pavblu at-risk. Amgen’s at-risk launch of Pavblu yielded … Continue reading Amgen’s At-Risk Launch of Pavblu Bolstered by Court Decision